Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by Noteableon Oct 19, 2024 3:43pm
66 Views
Post# 36273278

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:USA Inflation Reduction Act (IRA) 2022 Re: Biotech and China

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:USA Inflation Reduction Act (IRA) 2022 Re: Biotech and ChinaThe posts are all relevant to ONCY, the 13 years of market exclusivity at pelareorep would be granted as a biologic under the Inflation Reduction Act passed in 2022, and how China had employed McKinsey to try to usurp and thwart US innovation, for their own economic benefit. The actions of Dominic Barton were ones that McKinsey is now being held liable for by the US government, such as their global conflictrs of interest and advisement of China and Purdue Pharma.

Now McKinsey is advising that it is " Revamping Its China Operations Amid New Risks" and is cutting hundreds from its China workforce, as it trims state-linked clients and revises its 'win-at-all costs' and  "accelerant" business strategy for tougher times. This is happening amid public inquiries, increased government scrutiny, and diminishing public perception over its complicit business practices. 
<< Previous
Bullboard Posts
Next >>